𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutation analysis of 19 North American mucopolysaccharidosis type I patients: Identification of two additional frequent mutations

✍ Scribed by Lorne A. Clarke; Paul V. Nelson; Cara L. Warrington; C. Phillip Morris; John J. Hopwood; Hamish S. Scott


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
931 KB
Volume
3
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis


Communicated by Chrks R. Scriwer

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive genetic disorder caused by deficiency of the lysosomal glycosidase a-L-iduronidase. Patients with this disorder present with varied clinical phenotypes ranging from early severe onset of disease and death in early childhood to mild manifes. tations compatible with adult life. An understanding of the molecular basis of iduronidase deficiency and its correlation to clinical phenotype will improve prognostic prediction at diagnosis, aid in genetic counselling of families, and provide a framework to more accurately assess experimental treatment protocols. We have used the approach of single-strand conformational polymorphism analysis and direct sequencing of the a-L-iduronidase gene in an attempt to define the molecular basis of iduronidase deficiency in affected individuals. An initial series of 19 patients representing 35 independently segregating mutant alleles were studied. In addition to five previously identified mutations (W402X, Q70X, E274X, H82P, and P533R) two novel mutations (A75T and 474-2a-+g) were found. These seven mutations account for 71% of the mutant alleles and 53% of the genotypes in this group of patients. Analysis of a larger independently ascertained group of 103 MPS I patients, mainly of Northern European origin, revealed that together the two novel mutations account for 7% of mutant alleles and are associated with severe clinical phenotypes. These mutations are the most frequent MPS I mutations detected so far after W402X and Q70X. With the definition of these two mutations, a clear picture of the molecular heterogeneity of MI' S I is emerging.


πŸ“œ SIMILAR VOLUMES


Molecular analysis of 30 mucopolysacchar
✍ N. Venturi; A. Rovelli; R. Parini; F. Menni; F. Brambillasca; F. Bertagnolio; G. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 176 KB πŸ‘ 1 views

Mucopolysaccharidosis type I (MPS-I orMPS1) is an autosomal recessive condition characterized by a broad range of clinical symptoms. Molecular diagnosis of MPS-I is important for analyzing genotype-phenotype correlation and for selecting patients for innovative therapies. In this study we analyzed 3

Analysis of five mutations in 20 mucopol
✍ Laura Gort; Amparo ChabΓ‘s; M. Josep Coll πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 27 KB πŸ‘ 1 views

Mucopolysaccharidosis type I is a lysosomal storage disease due to a-L-Iduronidase deficiency. Three main phenotypes have been reported: Hurler (severe), Scheie (mild) and Hurler/Scheie (intermediate). High prevalence of mutations W402X and Q70X has been described. We studied these two mutations in

Identification of 9 novel IDS gene mutat
✍ Stanislav L. Karsten; Elena Voskoboeva; Britt-Marie Carlberg; Wim J. Kleijer; T πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 104 KB πŸ‘ 2 views

Hunter syndrome is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). The IDS deficiency can be caused by several different types of mutations in the IDS gene. We have performed a molecular and mutation analysis of a total of 19 unrelat

Identification and molecular characteriz
✍ G. Yogalingam; X.-H. Guo; V.J. Muller; D.A. Brooks; P.R. Clements; E.D. Kakkis; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 259 KB πŸ‘ 1 views

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase (IDUA). Mutations in the gene are responsible for the enzyme deficiency, which leads to the intralysosomal storage of the partially degraded glycosaminoglycans derm